Abstract
<jats:title>Abstract</jats:title><jats:p>Rivaroxaban is now licensed for the prevention of stroke and the treatment and prevention of DVT. In our New products review, Steve Chaplin presents the clinical data for its efficacy and adverse events related to these new indications, and specialists comment on its likely place in therapy.</jats:p>
Original language | English |
---|---|
Pages (from-to) | 14-23 |
Number of pages | 0 |
Journal | Prescriber |
Volume | 23 |
Issue number | 17 |
DOIs | |
Publication status | Published - 5 Sept 2012 |